analysis,Reporting < 2 yrs,Summary results < 1 yr,Any results reporting
Main analysis,"1097/2112, 51.9% (95%CI 49.8-54.1%)","48/2112, 2.3% (95%CI 1.7-3%)","1650/2112, 78.1% (95%CI 76.3-79.8%)"
Only RCTs,"790/1515, 52.1% (95%CI 49.6-54.7%)","32/1515, 2.1% (95%CI 1.5-3%)","1181/1515, 78% (95%CI 75.8-80%)"
Restricted to EUCTR,"267/431, 61.9% (95%CI 57.3-66.4%)","35/431, 8.1% (95%CI 5.9-11.1%)","389/431, 90.3% (95%CI 87.1-92.7%)"
Restricted to ClinicalTrials.gov,"830/1681, 49.4% (95%CI 47-51.8%)","13/1681, 0.8% (95%CI 0.5-1.3%)","1261/1681, 75% (95%CI 72.9-77%)"
Exclude trials with unknown status,"973/1824, 53.3% (95%CI 51.1-55.6%)","48/1824, 2.6% (95%CI 2-3.5%)","1490/1824, 81.7% (95%CI 79.8-83.4%)"
Only completed trials,"931/1675, 55.6% (95%CI 53.2-57.9%)","42/1675, 2.5% (95%CI 1.9-3.4%)","1418/1675, 84.7% (95%CI 82.9-86.3%)"
Primary completion date,"961/2045, 47% (95%CI 44.8-49.2%)","38/2045, 1.9% (95%CI 1.4-2.5%)","1600/2045, 78.2% (95%CI 76.4-80%)"
Restricted to ClinicalTrials.gov with actual completion date,"711/1411, 50.4% (95%CI 47.8-53%)","13/1411, 0.9% (95%CI 0.5-1.6%)","1112/1411, 78.8% (95%CI 76.6-80.9%)"
